MorphoSys has announced that its licensee Janssen has reported new data from two phase 3 studies of guselkumab in plaque psoriasis
Janssen presents results from phase 3 studies VOYAGE 2 and NAVIGATE in patients with moderate-to-severe plaque psoriasis at the American Academy of Dermatology (AAD) 2017 annual meeting.
Both studies met all primary endpoints, according to the abstracts submitted by Janssen to the AAD 2017 meeting.
According to a press release issued by Janssen, data from Janssen's VOYAGE 2 study "showed that patients treated with guselkumab experienced significant improvements in skin clearance and other measures of disease activity compared with placebo, and significantly greater improvements compared with the anti-tumor necrosis factor (TNF)-alpha treatment Humira(R) (adalimumab)."
Furthermore, according to Janssen's press release, data from Janssen's NAVIGATE study "showed that patients who had an inadequate response following treatment with the anti-interleukin (IL)-12/23 monoclonal antibody STELARA(R) (ustekinumab) and who then switched to guselkumab, showed significantly greater improvements in skin clearance compared with patients who continued to receive ustekinumab".
Guselkumab, a fully human anti-IL-23 monoclonal antibody developed by Janssen, was generated utilizing the HuCAL antibody library technology licensed from MorphoSys.
MorphoSys AG has announced that its licensee Janssen Research & Development, LLC (Janssen), has reported today results from two clinical phase 3 studies of guselkumab in patients with moderate-to-severe plaque psoriasis. Janssen will present the data from its VOYAGE 2 and NAVIGATE studies at the American Academy of Dermatology (AAD) annual meeting, held from March 3-7, 2017 in Orlando, Florida/USA. Guselkumab, a fully human anti-IL-23 monoclonal antibody developed by Janssen, was generated utilizing the HuCAL antibody library technology licensed from MorphoSys.
"Following on from the successful phase 3 VOYAGE 1 study in moderate to severe plaque psoriasis reported in October 2016, we are excited about the positive results from two more phase 3 studies with guselkumab reported by Janssen today", said Dr. Marlies Sproll, chief scientific officer of MorphoSys AG. "Plaque psoriasis is a chronic disease affecting millions of patients worldwide. We hope this therapy will be made available for patients living with moderate to severe plaque psoriasis and can make a contribution to treating their conditions. As previously reported by Janssen, the results of these studies were already included in Janssen's regulatory filings of guselkumab in the US and Europe".